-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral TherapyU.S. Centers for Disease Control and Prevention • Medical News
FDA Application Is Submitted for Evaluating HIV Treatment
January 13, 2004
Gilead Sciences Inc. has submitted an investigational new-drug application to the Food and Drug Administration to evaluate GS 9005, a potential protease inhibitor therapy that could be taken once daily. The drug's creator said GS 9005 might have a resistance profile that is distinct from commercially available drugs in the protease inhibitor class. Gilead plans to test the drug in healthy volunteers as well as HIV-positive patients. As an experimental drug, GS 9005 has not been determined to be safe or effective in humans for its intended use, Gilead said.
Back to other news for January 13, 2004
Search the Newsroom archive
Excerpted from:
Wall Street Journal
01.13.04
This article was provided by U.S. Centers for Disease Control and Prevention, and is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
  |
  |